AN2 Therapeutics
ANTX
AN2 Therapeutics (ANTX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Initiated Coverage | Buy | $9.00 | Jul 20, 2026 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $9.00 | May 14, 2026 |
| JMP Securities | Maintained | Market Outperform | $2.00 from $5.00 | May 5, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $5.00 | Mar 26, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $5.00 | Feb 25, 2025 |
| JMP Securities | Maintained | Market Outperform | $5.00 | Feb 3, 2025 |
| JMP Securities | Maintained | Market Outperform | $5.00 | Nov 19, 2024 |
| TD Cowen | Downgraded | Buy → Hold | — | Nov 18, 2024 |
| JMP Securities | Maintained | Market Outperform | $3.00 from $6.00 | Aug 9, 2024 |
| Leerink Partners | Upgraded | Market Perform → Outperform | — | Jul 3, 2024 |
| Evercore ISI Group | Maintained | In-Line | $2.00 from $7.00 | May 16, 2024 |
| JMP Securities | Upgraded | Market Perform → Market Outperform | $6.00 | Apr 2, 2024 |
| Oppenheimer | Maintained | Perform | — | Apr 1, 2024 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $7.00 from $23.00 | Feb 13, 2024 |
| JMP Securities | Downgraded | Market Outperform → Market Perform | — | Feb 12, 2024 |
| Oppenheimer | Downgraded | Outperform → Perform | — | Feb 12, 2024 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $7.00 from $25.00 | Feb 12, 2024 |
| JMP Securities | Initiated Coverage | Market Outperform | $30.00 | Jan 4, 2024 |
| Oppenheimer | Maintained | Outperform | $24.00 from $20.00 | Mar 30, 2023 |
Frequently asked questions
What is the latest analyst rating on ANTX?
On Jul 20, 2026, Guggenheim initiated coverage of AN2 Therapeutics at Buy with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.